November 1, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 

Tokyo, Apr 14, 2014 (JCN) - Kaneka Corporation in a joint research project with Keiji Numata, team leader of the Enzyme Research Team, Biomass Engineering Program Cooperation Division, Center for Sustainable Resource Science, RIKEN, and team, have successfully biosynthesized polyhydroxyalkanoic acid (PHA), a type of bioplastic, generated by microorganisms using degradation products of lignin, a plentiful component found in wood, as a carbon source.

As the world moves away from petroleum resources, the focus of research is shifting to the possibilities of production from plant resource. Much progress has been made in the degradation of plant resource such as cellulose to produce sugar.

However lignin, while freely available in wood, has attracted less interest due to low degradability and the issue of some degradation products being harmful to microorganisms.

Kaneka and RIKEN's Numata tried to synthesize PHA through biosynthesis by many microorganisms with a sole carbon source of aromatic compounds that make up lignin or similar aromatic compounds.

It was found that the bacteria Ralstonia eutropha H16 (Cupriavidus necator), known to be a producing strain for PHA, biosynthesized PHA from the lignin component 4-Hydroxybenzoic acid (4-HBA) and numerous other aromatic compounds. 4-HBA achieves good productivity, with PHA accumulation within the microorganism reaching around 63 wt% of dry cell weight.

Although the molecular weight of the biosynthesized PHA is slightly lower than that of PHA produced from sugar or vegetable oil, it showed properties that make it suitable for use in plastic products such as film.

The success opens the way for the development of basic technology that aims for microorganism material production using lignin, applications of which were difficult to date.

Also, this technology can be applied for the utilization of waste effluents including lignin degradation products from paper mills, etc., and by combining it with the wide variety of bio-refinery technologies, it is expected to spawn a new biomass industry.

By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Kaneka Corporation News  
  Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
  Kaneka Confirms Positive Effect of Q10 Against Fatigue  (Dec 3, 2012)
  Kaneka and Belgium's imec Develop Next-Generation Heterojunction Solar Cells  (June 14, 2012)
  Kaneka Builds Plant in Malaysia for Production of PI Film  (Apr 21, 2012)
  Kaneka to Establish Umbrella Hubs in Asia and the Americas  (Mar 12, 2012)
  AGC, ADEKA and Kaneka to Withdraw Investments from Kashima Denkai and Kashima PVC Monomer  (Dec 21, 2011)
  Kaneka, MOL and Mitsui Form CPVC JV in India  (Dec 7, 2011)
  Kaneka Develops High-efficiency Heterojunction Silicon Solar Cell  (Nov 28, 2011)
  Kaneka Sets Up Base in South Korea  (Nov 23, 2011)
  Kaneka Trials Production System for 100% Plant Based Biopolymer Product  (May 14, 2011)



 Recent  Biotech News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Biotech news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)